A Phase 3 interventional study of Tislelizumab and Pamiparib in Advanced Malignancies, sponsored by BeOne Medicines. Completed at 106 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by BeOne Medicines · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).
For the purposes of this study, "study treatment" will refer to all investigational agents. A parent study is defined as the original BeiGene- or BeOne-sponsored clinical trial in which the participant was initially enrolled and received BeiGene or BeOne investigational drugs (with or without other treatments).
Note: Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
The first dose of study treatment in the LTE study will be received within the treatment interruption period allowed by the parent study:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tislelizumab
Drug: Pamiparib
Drug: Sitravatinib
Drug: BGB-15025
Drug: Zanidatamab
Drug: Pamiparib · Drug: Temozolomide
Drug: Tislelizumab · Drug: Pamiparib
Drug: Tislelizumab · Drug: Sitravatinib
Drug: Tislelizumab · Drug: Ociperlimab
Drug: Tislelizumab · Drug: BAT1706
Drug: Tislelizumab · Drug: Fruquintinib
Drug: Tislelizumab · Drug: BGB-A445
Drug: Tislelizumab · Drug: Surzebiclimab
Drug: Tislelizumab · Drug: BGB-15025
Drug: Tislelizumab · Drug: Lenvatinib
Drug: Tislelizumab · Drug: Zanidatamab
Drug: Tislelizumab · Drug: LBL-007
Drug: Tislelizumab · Drug: Surzebiclimab · Drug: LBL-007
Administered intravenously.
Also known as: BGB-A317
Administered orally.
Also known as: BGB-290
Administered orally.
Administered orally.
Administered intravenously.
Also known as: BGB-A1217
Administered intravenously.
Administered orally.
Administered orally.
Administered intravenously.
Also known as: ZW25
Administered intravenously.
Also known as: Gimistotug
Administered intravenously.
Also known as: BGB-A425
Administered orally.
Administered intravenously.
Also known as: Alcestobart
Number of Participants with Immune-Mediated Adverse Events, Serious Adverse Events, and Adverse Events Grade 3 or Higher
Safety as assessed by the number of participants with immune-mediated adverse events (imAEs), ≥ Grade 3 adverse events, and serious adverse events.
Time frame: up to 7 years
Showing the first 100 of 106 sites across 13 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beonemedicines.com
No publications or documents are linked to this record.
Ran from Dec 2019 to primary completion in May 2026, 77 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tislelizumab · Pamiparib · Sitravatinib · Zanidatamab